See Full Report below….
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our
members in the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%
for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our
VIP SMS/text alert service for free, simply text the word “Alerts
” to the phone number 25827 from your cell phone.
Anacor Pharmaceuticals Inc (NASDAQ:ANAC)‘s stock had its “buy” rating reissued by research analysts at Mizuho in a research note issued on Thursday, AnalystRatings.NETreports. They presently have a $102.00 price target on the biopharmaceutical company’s stock. Mizuho’s price target points to a potential upside of 78.70% from the stock’s previous close.
Several other analysts also recently issued reports on the company. Wedbush reissued an “outperform” rating and issued a $190.00 price target on shares of Anacor Pharmaceuticals in a research note on Friday, December 4th. Jefferies Group reiterated a “buy” rating and set a $105.00 price objective on shares of Anacor Pharmaceuticals in a report on Thursday, March 10th. Cowen and Company reissued an “outperform” rating on shares of Anacor Pharmaceuticals in a research report on Tuesday, March 1st. Finally, Zacks Investment Research upgraded Anacor Pharmaceuticals from a “sell” rating to a “hold” rating and set a $128.00 target price on the stock in a research note on Tuesday, January 5th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $142.50.
Anacor Pharmaceuticals (NASDAQ:ANAC) opened at 57.08 on Thursday. The stock’s 50 day moving average price is $63.26 and its 200 day moving average price is $95.29. The company’s market capitalization is $2.52 billion. Anacor Pharmaceuticals has a 12-month low of $52.00 and a 12-month high of $156.93.
Anacor Pharmaceuticals (NASDAQ:ANAC) last issued its quarterly earnings data on Monday, February 29th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by $0.13. During the same period last year, the company earned ($0.24) earnings per share. The firm had revenue of $21.20 million for the quarter, compared to the consensus estimate of $27.93 million. The firm’s quarterly revenue was up 120.8% compared to the same quarter last year. On average, equities research analysts anticipate that Anacor Pharmaceuticals will post ($1.19) earnings per share for the current fiscal year.
A number of large investors have recently modified their holdings of ANAC. CenturyLink Investment Management Co increased its stake in shares of Anacor Pharmaceuticals by 7.8% in the fourth quarter. CenturyLink Investment Management Co now owns 2,469 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 178 shares during the period. Creative Planning raised its stake in Anacor Pharmaceuticals by 30.7% in the fourth quarter. Creative Planning now owns 2,518 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 591 shares in the last quarter. Paradigm Asset Management Co. LLC boosted its stake in Anacor Pharmaceuticals by 890.5% in the fourth quarter. Paradigm Asset Management Co. LLC now owns 10,400 shares of the biopharmaceutical company’s stock worth $1,175,000 after buying an additional 9,350 shares during the last quarter. Vident Investment Advisory LLC acquired a new stake in Anacor Pharmaceuticals during the fourth quarter worth about $1,304,000. Finally, AlpInvest Partners B.V. acquired a new stake in Anacor Pharmaceuticals during the fourth quarter worth about $1,305,000.
In other news, CEO Paul L. Berns sold 37,500 shares of the business’s stock in a transaction dated Tuesday, March 22nd. The shares were sold at an average price of $60.31, for a total transaction of $2,261,625.00. Following the transaction, the chief executive officer now directly owns 258,111 shares in the company, valued at approximately $15,566,674.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Lee Zane sold 1,466 shares of the business’s stock in a transaction dated Friday, January 15th. The stock was sold at an average price of $89.57, for a total transaction of $131,309.62. Following the transaction, the senior vice president now owns 27,281 shares in the company, valued at $2,443,559.17. The disclosure for this sale can be found here.
Anacor Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. The Company’s lead product candidate, AN2728 is an investigational non-steroidal topical PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis and psoriasis.
Source: South Florida Hedge Fund Managers
Broad Street Alerts has not been compensated for the mention of _ANAC__ and we do not hold any positions.
